E2212

E2212 is a novel small molecule γ-secretase modulator developed by Eisai for the treatment of Alzheimer's disease. Its mechanism of action involves modulation of γ-secretase activity, leading to a reduction in plasma concentrations of amyloid-beta (Aβ) peptides, particularly Aβ(x-42), which are implicated in the pathogenesis of Alzheimer's disease. E2212 has been evaluated in phase 1 clinical trials and was found to be well tolerated with no significant safety concerns at single doses up to 250 mg. The drug is rapidly absorbed and exhibits biphasic pharmacokinetics with a terminal half-life ranging from approximately 12.5 to 19 hours[1][2][3][5].